Search

Micah Bodner Phones & Addresses

  • 2061 Eastwood Ln, Eugene, OR 97401
  • 85151 Ridgeway Rd, Pleasant Hill, OR 97455
  • Vida, OR
  • 3702 Kimble Rd, Baltimore, MD 21218 (410) 338-0928
  • 2806 Halcyon Ave, Baltimore, MD 21214 (410) 444-4961
  • Dexter, OR
  • Lime, OR
  • 2490 Agate St, Eugene, OR 97403 (541) 434-9499

Work

Company: Bodner wine company 2010 to 2013 Position: Owner

Education

Degree: Doctorates, Doctor of Philosophy School / High School: The Johns Hopkins University 2003 to 2009 Specialities: Philosophy, Organic Chemistry

Skills

Chemistry • Biochemistry • Molecular Biology • Protein Purification • Uv/Vis • Mass Spectrometry • Hplc • Protein Expression • Research • Cell Culture • Chromatography • Analytical Chemistry • Bioinformatics • Pcr • Microsoft Office

Industries

Biotechnology

Resumes

Resumes

Micah Bodner Photo 1

Associate Director Of Chemistry

View page
Location:
2061 Eastwood Ln, Eugene, OR 97401
Industry:
Biotechnology
Work:
Bodner Wine Company 2010 - 2013
Owner

University of Oregon Nov 2010 - Nov 2012
Postdoctoral Research Associate

Cascade Custom Chemistry (Organic Consultants, Inc.) Nov 2010 - Nov 2012
Senior Chemist

Nov 2010 - Nov 2012
Associate Director of Chemistry
Education:
The Johns Hopkins University 2003 - 2009
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry
University of Oregon 1999 - 2003
Bachelors, Bachelor of Science, Biochemistry
Pleasant Hill High School
The Johns Hopkins University
Skills:
Chemistry
Biochemistry
Molecular Biology
Protein Purification
Uv/Vis
Mass Spectrometry
Hplc
Protein Expression
Research
Cell Culture
Chromatography
Analytical Chemistry
Bioinformatics
Pcr
Microsoft Office

Publications

Us Patents

Aryl Diamidines And Prodrugs Thereof For Treating Myotonic Dystrophy

View page
US Patent:
20130281462, Oct 24, 2013
Filed:
Apr 19, 2013
Appl. No.:
13/866863
Inventors:
Micah J. Bodner - Vida OR, US
Assignee:
University of Oregon - Eugene OR
International Classification:
C07C 257/18
US Classification:
51425503, 564243, 514636, 549491, 514471, 544392, 548440, 514411
Abstract:
Disclosed herein are compounds (for example, diamidine derivatives and prodrugs) and methods of use thereof, for example in treating muscular dystrophy (DM) or disease caused by a toxic RNA in a subject. In some embodiments, the methods include administering an effective amount of one of more of the disclosed compounds to a subject to treat or inhibit DM or a disease caused by or associated with toxic RNA, such as DM1, DM2, spinocerebellar ataxia type 8 (SCA8), fragile X tremor ataxia syndrome (FXTAS), or Huntington disease-like 2 (HLD2). In some examples, the methods include selecting a subject for treatment, for example selecting a subject with DM1, DM2, SCA8, FXTAS, or HLD2.

Method For Late Introduction Of The (8R)-Hydroxyl Group Carbapenem Beta-Lactam Antibiotic Synthesis

View page
US Patent:
20130066066, Mar 14, 2013
Filed:
Dec 13, 2010
Appl. No.:
13/515114
Inventors:
Craig Arthur Townsend - Baltimore MD, US
Micah Jeffrey Bodner - Dexter OR, US
Ryan Martin Phelan - Baltimore MD, US
Michael Francis Freeman - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C12P 17/10
C07D 477/00
US Classification:
540350, 435121
Abstract:
The presently disclosed subject matter demonstrates that ThnG and ThnQ enzymes encoded by the thienamycin gene cluster in oxidize the C-2 and C-6 moieties of carbapenems, respectively. ThnQ stereospecifically hydroxylates PS-5 giving N-acetyl thienamycin. ThnG catalyzes sequential desaturation and sulfoxidation of PS-5, giving PS-7 and its sulfoxide. The ThnG and ThnQ enzymes are relatively substrate selective, but give rise to the oxidative diversity of carbapenems produced by and orthologues likely function similarly in allied

Mechanisms Of Antimicrobial Susceptibility6

View page
US Patent:
20180112281, Apr 26, 2018
Filed:
Dec 20, 2017
Appl. No.:
15/848391
Inventors:
- Pleasanton CA, US
Micah Bodner - Eugene OR, US
Jeremiah Marsden - Eugene OR, US
International Classification:
C12Q 1/6897
C12Q 1/689
C12N 7/00
C12Q 1/66
C12Q 1/04
Abstract:
Disclosed herein are methods and compositions for determining the presence or absence of a mechanism of antimicrobial resistance in a sample.

Mechanisms Of Antimicrobial Susceptibility

View page
US Patent:
20160348187, Dec 1, 2016
Filed:
May 23, 2016
Appl. No.:
15/161857
Inventors:
- Los Gatos CA, US
Micah Bodner - Eugene OR, US
Jeremiah Marsden - Eugene OR, US
International Classification:
C12Q 1/68
C12Q 1/04
C12Q 1/66
Abstract:
Disclosed herein are methods and compositions for determining the presence or absence of a mechanism of antimicrobial resistance in a sample.

Method For Late Introduction Of The (8R) Hydroxyl Group Carbapenem Beta-Lactam Antibiotic Synthesis

View page
US Patent:
20160083760, Mar 24, 2016
Filed:
Sep 21, 2015
Appl. No.:
14/860103
Inventors:
- Baltimore MD, US
MICAH JEFFREY BODNER - DEXTER OR, US
RYAN MARTIN PHELAN - Emeryville CA, US
MICHAEL FRANCIS FREEMAN - Bonn, DE
Assignee:
THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD
International Classification:
C12P 17/10
C07D 477/20
Abstract:
The presently disclosed subject matter demonstrates that ThnG and ThnQ enzymes encoded by the thienamycin gene cluster in oxidize the C-2 and C-6 moieties of carbapenems, respectively. ThnQ stereospecifically hydroxylates PS-5 giving N-acetyl thienamycin. ThnG catalyzes sequential desaturation and sulfoxidation of PS-5, giving PS-7 and its sulfoxide. The ThnG and ThnQ enzymes are relatively substrate selective, but give rise to the oxidative diversity of carbapenems produced by , and orthologues likely function similarly in allied
Micah J Bodner from Eugene, OR, age ~44 Get Report